<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 3</label>
 <caption>
  <p>Clinical trials/studies in progression on using chloroquine (CQ) or hydroxychloroquine (HCQ) as antiviral agents</p>
 </caption>
 <alt-text id="alttext0030">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Name
     <xref rid="tbl3fna" ref-type="table-fn">a</xref>
    </th>
    <th>Reference ID</th>
    <th>Source</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Post-exposure prophylaxis for SARS-Coronavirus-2</td>
    <td>NCT04308668</td>
    <td>ClinicalTrials.gov</td>
   </tr>
   <tr>
    <td>Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID-19)</td>
    <td>NCT04307693</td>
    <td>ClinicalTrials.gov</td>
   </tr>
   <tr>
    <td>Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting</td>
    <td>NCT04303507</td>
    <td>ClinicalTrials.gov</td>
   </tr>
   <tr>
    <td>Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID-19 epidemic</td>
    <td>NCT04304053</td>
    <td>ClinicalTrials.gov</td>
   </tr>
   <tr>
    <td>Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquine for treatment of COVID19: a randomized control trial</td>
    <td>NCT04303299</td>
    <td>ClinicalTrials.gov</td>
   </tr>
   <tr>
    <td>New treatment for radical cure of dengue fever with antiviral and anti-cytokine</td>
    <td>CTRI/2017/12/010834</td>
    <td>WHO ICTRP</td>
   </tr>
   <tr>
    <td>A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVID-19)</td>
    <td>ChiCTR2000030054</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>A prospective, randomized, open-label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000029992</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>Evaluation the efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate chloroquine in mild and common patients with novel coronavirus pneumonia (COVID-19): a randomized, open-label, parallel, controlled trial</td>
    <td>ChiCTR2000029899</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>Evaluation the efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate chloroquine in severe patients with novel coronavirus pneumonia (COVID-19): a randomized, open-label, parallel, controlled trial</td>
    <td>ChiCTR2000029898</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000029803</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000031204</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>A randomized controlled trial for favipiravir tablets combine with chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000030987</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>Randomized controlled trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000030718</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>Clinical study of chloroquine phosphate in the treatment of severe novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000029988</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000029975</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>A single-blind, randomized, controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia 2019 (COVID-19)</td>
    <td>ChiCTR2000029939</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>A single-arm clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia 2019 (COVID-19)</td>
    <td>ChiCTR2000029935</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>Efficacy of chloroquine and lopinavir/ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study</td>
    <td>ChiCTR2000029741</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000029609</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
   <tr>
    <td>Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)</td>
    <td>ChiCTR2000029542</td>
    <td>Chinese Clinical Trials Registry</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tbl3fna">
   <label>a</label>
   <p id="ntpara0015">The names were extracted as they appeared on relevant databases without any language corrections.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
